http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107137705-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16734 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0686 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 |
| filingDate | 2017-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107137705-B |
| titleOfInvention | The production method of pseudorabies gE gene delection viral inactivation vaccines |
| abstract | The present invention relates to the method that pseudorabies gE gene delection viral inactivation vaccines are produced with bhk cell system, it comprises the following steps：It will be cultivated after BHK21 cell recoveries in access rolling bottle to cell after growing in flakes, access pseudorabies gE gene delections are viral, continue to cultivate, treat that cytopathy CPE up to more than 90%, harvesting venom, the virus liquid of harvest is concentrated, inactivated, be degerming, finished product is made, produces.Viral level using the pseudorabies gE gene delection virus liquids of immunogenic production process provided by the invention harvest is high, up to >=10 7.2 TCID 50 / mL, and there is stronger immunogenicity, it is not necessary to the immune effect that immunopotentiator can reach is added, can promote to secrete neutralizing antibody in vivo after immune, immune protective rate reaches 100%, and vaccine potency evaluation criterion is fully achieved. |
| priorityDate | 2017-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.